GE Healthcare’s Life Sciences’ European manufacturing and distribution site in Pasching, Austria, for sterile liquids has expanded its capabilities to include production of large volumes of buffers, process liquids, and cell culture media. It also launched a production service for prototype cell culture media and buffers. The Pasching facility serves biopharmaceutical companies in over 40 countries across Europe, Africa, and the Middle East.

“Our aim is to accelerate development and scale-up for our biomanufacturing customers by providing simplified, flexible services both in Europe and in other regions,” said David Radspinner, Ph.D., general manager of bioprocess cell culture at GE Healthcare’s Life Sciences. “The capabilities of our Pasching facility will enable us to seamlessly support our customers globally, ensuring security of supply with multiple manufacturing sites that are qualified and validated to the same quality standards.”

GE’s additional production capacity at Pasching has been developed over 2 years, with an investment of $4.3 million.








This site uses Akismet to reduce spam. Learn how your comment data is processed.